Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Calypte Biomedical Corporation (CALY) -- Ignore unavailable to you. Want to Upgrade?

To: Caxton Rhodes who wrote (318)	12/11/1998 9:49:00 PM
From: Sherman Chen	Respond to of 381

OT: Well at least you made about 90% on them. Market looking shaky right now, but some strength in tech sector.

To: Caxton Rhodes who wrote (318)	12/15/1998 5:41:00 PM
From: Sherman Chen	Read Replies (1) \| Respond to of 381

Do you think this is good? Tuesday December 15, 4:43 pm Eastern Time Company Press Release Calypte Biomedical Corporation Adopts Stockholder Rights Plan BERKELEY, Calif.--(BW HealthWire)--Dec. 15, 1998--Calypte Biomedical Corporation (Nasdaq:CALY - news) today adopted a Stockholder Rights Plan to assist its stockholders in realizing fair value and equal treatment in the event of any attempted takeover of the Company and to protect the Company and its stockholders against coercive takeover tactics. Under the Stockholder Rights Plan, a dividend of one Preferred Stock Purchase Right is being declared for each share of Common Stock outstanding at the close of business on January 5, 1999. No separate certificates evidencing the Rights will be issued unless and until they become exercisable. The Rights generally will not become exercisable until a person or group acquires 15% or more of the Common Stock of the Company in a transaction that is not approved in advance by the Board of Directors. In that event, each Right will entitle the holder, other than the unapproved acquiror and its affiliates, to buy Common Stock of the Company at 50% of its market value for the Right's then current exercise price (initially $15.00, subject to adjustment). In addition, if the Rights were triggered by such a non-approved acquisition and the Company were thereafter to be acquired in a merger in which all stockholders were not treated alike, stockholders with unexercised Rights, other than the unapproved acquiror and its affiliates, would be entitled to purchase common stock of the acquiror with a value of twice the exercise price of the Rights. The Company's Board of Directors may redeem the Rights for a nominal amount at any time prior to an event that causes the Rights to become exercisable. The Rights will expire on December 15, 2008. Calypte Biomedical Corporation is a Berkeley, California-based health care company dedicated to the development and commercialization of urine-based diagnostic products and services for HIV-1, sexually transmitted diseases, and other chronic illnesses.